| Trial ID: | L4120 |
| Source ID: | NCT06422624
|
| Associated Drug: |
Semaglutide Extended-Release For Injectable Suspension, 1 Mg
|
| Title: |
A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects
|
| Acronym: |
|
| Status: |
NOT_YET_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Semaglutide Extended-release for Injectable Suspension, 1 mg|DRUG: Semaglutide Extended-release for Injectable Suspension, 4 mg|DRUG: Semaglutide Extended-release for Injectable Suspension, 8 mg
|
| Outcome Measures: |
Primary: Cmax, Maximum plasma concentration, From time zero up to the last time point with measurable concentration|AUC0-t, Area under the plasma concentration time curve from time zero to the last measurable concentration, From time zero up to the last time point with measurable concentration|AUC0-inf, Area under the plasma concentration-time curve from time zero to infinity, From time zero up to the last time point with measurable concentration |
|
| Sponsor/Collaborators: |
Sponsor: Bostal Drug Delivery Co., Ltd
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
14
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-08
|
| Completion Date: |
2024-11
|
| Results First Posted: |
|
| Last Update Posted: |
2024-05-22
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT06422624
|
